As the global debate intensifies over whether multi-million-dollar drugs are worth the money, big pharma needs to improve transparency over... Read this story
As the global debate intensifies over whether multi-million-dollar drugs are worth the money, big pharma needs to improve transparency over... Read this story
More from SWI swissinfo.ch | Article Business disease healthcare policy medical service medicine beat-Multinational companies Multinationals patient pharmaceutical Pharmaceutical industry Medicine Novartis Spinal muscular atrophy